Safety, tolerability, and efficacy of atogepant added to onabotulinumtoxinA for the preventive treatment of chronic migraine: A phase 3, multicenter, 24-week, open-label study - PubMed
6 hours ago
- #atogepant
- #onabotulinumtoxinA
- #chronic migraine
- This phase 3 study evaluated adding atogepant to onabotulinumtoxinA for chronic migraine prevention.
- Combination therapy was safe and well-tolerated, with a 65.3% incidence of treatment-emergent adverse events, primarily constipation and nausea.
- Efficacy showed significant reductions in monthly migraine days and headache days over 24 weeks.
- Responder rates improved, with over 50% of participants achieving at least a 50% reduction in migraine days.
- The study supports combining treatments with different mechanisms for better chronic migraine management.